Literature DB >> 7868376

Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors.

J M Tiercy1, N Djavad, N Rufer, D E Speiser, M Jeannet, E Roosnek.   

Abstract

We have set up a simple PCR-SSO oligotyping procedure that is able to discriminate ten HLA-A2 (2 PCR/11 probes), two HLA-A3 (1 PCR/1 probe), and two HLA-B44 subtypes (1 PCR/2 probes). The frequency of these subtypes has been determined in a large panel of local blood donors and leukemic patients in combination with their unrelated potential donors. A*0201 and A*0301 were the predominant subtypes (> 95%) for A2 and A3, respectively. B*4402 occurred twice as frequently as B*4403. A2 and B44 subtype mismatches were analyzed in a group of 30 patients and their 116 unrelated potential donors who were matched serologically (low-stringency matching: AB without splits, DR1-10). For seven patients (23%) at least one A2- or B44-subtype-mismatched donor was found. For two of these patients (7%), the subtype-mismatched donor would have been considered as compatible on the basis of high stringency matching (AB splits, DRB1 subtypes, DRB3/B5). For one patient of Mediterranean origin, all five donors recruited from a north European registry (matched with high stringency) appeared to be subtype incompatible (A*0201/A*0205). The rather low percentage of A2- and B4-subtype mismatches in DRB1/B3/B5 matched combinations confirms the significance of linkage disequilibria of HLA antigens. Because unrelated donor selection is done through international registries, however, class I subtyping might be necessary when individuals originate from different geographic areas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7868376     DOI: 10.1016/0198-8859(94)90038-8

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

1.  A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.

Authors:  Giorgio Parmiani; Lorenzo Pilla; Angelo Corti; Claudio Doglioni; Carolina Cimminiello; Matteo Bellone; Danilo Parolini; Vincenzo Russo; Filippo Capocefalo; Cristina Maccalli
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

2.  Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.

Authors:  Tiziano Di Tomaso; Stefania Mazzoleni; Ena Wang; Gloria Sovena; Daniela Clavenna; Alberto Franzin; Pietro Mortini; Soldano Ferrone; Claudio Doglioni; Francesco M Marincola; Rossella Galli; Giorgio Parmiani; Cristina Maccalli
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

3.  A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.

Authors:  H Dolstra; H Fredrix; F Maas; P G Coulie; F Brasseur; E Mensink; G J Adema; T M de Witte; C G Figdor; E van de Wiel-van Kemenade
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

4.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.

Authors:  Sachet A Shukla; Michael S Rooney; Mohini Rajasagi; Grace Tiao; Philip M Dixon; Michael S Lawrence; Jonathan Stevens; William J Lane; Jamie L Dellagatta; Scott Steelman; Carrie Sougnez; Kristian Cibulskis; Adam Kiezun; Nir Hacohen; Vladimir Brusic; Catherine J Wu; Gad Getz
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

5.  Deciphering the fine nucleotide diversity of full HLA class I and class II genes in a well-documented population from sub-Saharan Africa.

Authors:  T Goeury; L E Creary; L Brunet; M Galan; M Pasquier; B Kervaire; A Langaney; J-M Tiercy; M A Fernández-Viña; J M Nunes; A Sanchez-Mazas
Journal:  HLA       Date:  2018-01       Impact factor: 4.513

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.